‘Decoy’ Protein Offers New Treatment Approach For Covid-19 – (Forbes.com)
Recently William Haseltine wrote an excellent article on Forbes regarding ACE2 research and the development of therapeutics for SARS-Cov2. The article includes a link to research performed by Cyrus ...
Cyrus Biotechnology CEO Lucas Nivon featured in Fierce Biotech Webinar
Date: Thursday, February 3, 2022Time: 2pm ET / 11am PTDuration: 1 HourSign up here to go to the webinarImproving the discovery of novel drugs with ...
Cyrus ACE2.v2.4 candidate’s in vivo activity and prevention of lung damage demonstrated by University of Illinois College of Medicine department of Pharmacology – (Nature.com)
https://www.nature.com/articles/s41589-021-00965-6 ...
Cyrus Biotechnology’s COVID therapeutic lead, ACE2.v2.4, strongly binds and neutralizes SARS-CoV-2 omicron variant potentially providing long term protection
SEATTLE, WA - (BUSINESS WIRE) - Cyrus Biotechnology, Inc., a Seattle-based biotechnology firm with a proprietary platform for biologics discovery that combines software, AI and large-scale parallel ...
Cyrus Biotechnology Announces $18M Financing and Acquisition of Orthogonal Biologics to Form an Integrated Software-Driven Pre-Clinical-Stage Drug Discovery Firm – (Businesswire)
SEATTLE, WA December 6, 2021 -- Cyrus Biotechnology, Inc., a Seattle-based biotechnology firm with a proprietary software platform for biologics discovery, today announced the closing of a $18M Series ...
Selecta Biosciences and Cyrus Biotechnology Enter Collaboration to Create Novel Engineered Therapeutic Proteins
- First collaboration program, leveraging Cyrus’ de novo computational approach to create proprietary IL-2 protein agonist targeting autoimmune and other deleterious immune conditions--Preclinical ...
Scientific Summary: Cyrus NextGen Antibody structure prediction beats Schrodinger and others in a large independent benchmark
Over the last few years Cyrus has worked on problems on a range of proteins from enzymes to non-antibody biologics to vaccines to some antibody work. However most biologic drugs are monoclonal ...
New Cyrus “NextGen” antibody software outperforms the competition in third party test with BIOCAD biotechnology
SummaryCyrus has developed a “NextGen” antibody structure prediction tool (NextGen) based on the RosettaCM “hybridize” algorithm (1). Cyrus customized and modified RosettaCM for antibody ...
Use of Cyrus Bench cited in review article of human diseases caused by formin INF2 mutations
SEATTLE, WA July 13, 2020 — Cyrus Bench®, Cyrus Biotechnology, Inc.’s SaaS platform for protein engineering, has been used in a recent review article in Cellular and Molecular Life Sciences to ...
Prediction of protein mutational free energy: benchmark and sampling improvements increase classification accuracy
SEATTLE, WA March 20, 2020 — Software to predict the change in protein stability upon point mutation is a valuable tool for a number of biotechnological and scientific problems. To facilitate the ...
No post found
sign up for our newsletter now!
RECENT COMMENTS